These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
650 related articles for article (PubMed ID: 7563150)
1. Incidence of second cancers in patients treated for Hodgkin's disease. Boivin JF; Hutchison GB; Zauber AG; Bernstein L; Davis FG; Michel RP; Zanke B; Tan CT; Fuller LM; Mauch P J Natl Cancer Inst; 1995 May; 87(10):732-41. PubMed ID: 7563150 [TBL] [Abstract][Full Text] [Related]
2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578 [TBL] [Abstract][Full Text] [Related]
3. Second cancer among long-term survivors from Hodgkin's disease. Nyandoto P; Muhonen T; Joensuu H Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):373-8. PubMed ID: 9788418 [TBL] [Abstract][Full Text] [Related]
4. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. Swerdlow AJ; Barber JA; Horwich A; Cunningham D; Milan S; Omar RZ Br J Cancer; 1997; 75(1):116-23. PubMed ID: 9000608 [TBL] [Abstract][Full Text] [Related]
5. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773 [TBL] [Abstract][Full Text] [Related]
6. Breast cancer after treatment of Hodgkin's disease. Hancock SL; Tucker MA; Hoppe RT J Natl Cancer Inst; 1993 Jan; 85(1):25-31. PubMed ID: 8416252 [TBL] [Abstract][Full Text] [Related]
7. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. Swerdlow AJ; Barber JA; Hudson GV; Cunningham D; Gupta RK; Hancock BW; Horwich A; Lister TA; Linch DC J Clin Oncol; 2000 Feb; 18(3):498-509. PubMed ID: 10653865 [TBL] [Abstract][Full Text] [Related]
8. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. van Leeuwen FE; Klokman WJ; Hagenbeek A; Noyon R; van den Belt-Dusebout AW; van Kerkhoff EH; van Heerde P; Somers R J Clin Oncol; 1994 Feb; 12(2):312-25. PubMed ID: 8113838 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the risk of solid tumor following Hodgkin's disease. Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084 [TBL] [Abstract][Full Text] [Related]
10. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496 [TBL] [Abstract][Full Text] [Related]
11. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Mauch PM; Kalish LA; Marcus KC; Coleman CN; Shulman LN; Krill E; Come S; Silver B; Canellos GP; Tarbell NJ Blood; 1996 May; 87(9):3625-32. PubMed ID: 8611686 [TBL] [Abstract][Full Text] [Related]
12. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? Dietrich PY; Henry-Amar M; Cosset JM; Bodis S; Bosq J; Hayat M Blood; 1994 Aug; 84(4):1209-15. PubMed ID: 8049435 [TBL] [Abstract][Full Text] [Related]
13. Can MOPP be replaced in the treatment of advanced Hodgkin's disease? Canellos GP Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509 [TBL] [Abstract][Full Text] [Related]
14. Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Chronowski GM; Wilder RB; Levy LB; Atkinson EN; Ha CS; Hagemeister FB; Barista I; Rodriguez MA; Sarris AH; Hess MA; Cabanillas F; Cox JD Am J Clin Oncol; 2004 Feb; 27(1):73-80. PubMed ID: 14758137 [TBL] [Abstract][Full Text] [Related]
15. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group. Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137 [TBL] [Abstract][Full Text] [Related]
16. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. Valagussa P; Santoro A; Fossati-Bellani F; Banfi A; Bonadonna G J Clin Oncol; 1986 Jun; 4(6):830-7. PubMed ID: 3711960 [TBL] [Abstract][Full Text] [Related]
17. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. Swerdlow AJ; Douglas AJ; Hudson GV; Hudson BV; Bennett MH; MacLennan KA BMJ; 1992 May; 304(6835):1137-43. PubMed ID: 1392790 [TBL] [Abstract][Full Text] [Related]
19. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia. Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437 [TBL] [Abstract][Full Text] [Related]
20. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. Swerdlow AJ; Schoemaker MJ; Allerton R; Horwich A; Barber JA; Cunningham D; Lister TA; Rohatiner AZ; Vaughan Hudson G; Williams MV; Linch DC J Clin Oncol; 2001 Mar; 19(6):1610-8. PubMed ID: 11250989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]